What intervention on the use or dosing of antibiotics work to decrease resistance? Jan. 18, 2007 Sung-Ching Pan.

Slides:



Advertisements
Similar presentations
TREATMENT FOR SUPERIMPOSED PSEUDOMONAS AERUGINOSA INFECTION.
Advertisements

The Resistance Problem PRSP = Penicillin Resistant Strep. pneumoniae QRSP = Quinolone Resistant Strep. pneumoniae MRSA = Methicillin Resistant Staph.
BETHLEHEM UNIVERSITY Second Neonatal Gathering Fall 2007.
Role of MRSA Swabs for De-escalation of Antibiotics in HCAP
Animal Model PK/PD: A Tool for Drug Development
1 Benoît GUERY Infectious Diseases CHRU Lille Antibiotic strategies How to treat Multi-drug-resistant Pseudomonas.
Jennifer Ott, PharmD, BCPS Clinical Pharmacy Specialist, Infectious Diseases Eastern Maine Medical Center Bangor, ME
Ventilator Associated Pneumonia (VAP)
Enoch Omonge University of Nairobi
Subtle Imipenem Resistance In an ICU Outbreak of Acinetobacter-baumanii calcoaceticus (ACBC) Sandy J. Close, Pharm.D., BCPS, Steven J. Martin, Pharm.D.,
What do case-control studies tell us about risk factors for antibiotic resistance? Christie Y. Jeon EPI502 Jan 22 nd, 2008.
Implementation of a Hospital Paediatric Antimicrobial Stewardship Program Sydney Children’s Hospital Mostaghim M, Snelling T, McMullan B, Palasanthiran.
What ecological studies can & can’t tell us Justin O’Hagan 2 nd year Epi Doctoral Student.
Antibiotic control Thursday 1/17/07. Antibiotic use Antibiotic resistance How can we change / reduce Ab use??? Will it reduce Ab resistance???
Antimicrobial resistance surveillance in Ireland Results of invasive Pseudomonas aeruginosa infection (blood/CSF) surveillance, 2009 **** Data as of 01/12/2010.
Overview of Use of PK-PD in Streamlining Drug Development William A. Craig Professor of Medicine University of Wisconsin.
Chapter 10: Restricting antibiotic use and optimizing dosing.
Pharmacodynamics of Antibiotics
Evidence Based Guidelines at PHD related to Infectious Disease Edward L. Goodman, MD.
CHOICE OF ANTIBIOTICS IN THE VIEW OF DEVELOPING ANTIBIOTIC RESISTANCE Dr. Jolanta Miciulevičienė Vilnius City Clinical Hospital National Public Health.
Top 5 Papers in Infectious Diseases Pharmacotherapy: A Review of 2013 for the General Practitioner Sharanie V. Sims, Pharm.D., BCPS (AQ-ID) Infectious.
MDR Organisms in Holy Family Hospital Rawalpindi
Introduction to Antimicrobial Resistance and Antibiotic Stewardship
IDSA / ISAP / FDA Workshop on Antimicrobial Drug Development Update 2004 Edward Cox, MD MPH ODE IV Center for Drug Evaluation and Research US Food and.
Antimicrobial Stewardship in Long Term Care Shira Doron, MD Assistant Professor of Medicine Associate Hospital Epidemiologist Tufts Medical Center.
“Emerging infections, the re-emergence of infectious diseases previously considered to be under control, and the alarming trend of antibiotic resistance….require.
1 Developed by Consensus III Medical Expert Group : Gert Höffken, Universitat Dresden, Dresden, Germany George Karam, Louisiana State University Medical.
Designs to determine the impact of Ab resistance How do we correctly measure the outcomes of antibiotic resistance?
Antimicrobial Stewardship St. Mary’s Hospital Infection Control Committee.
Infection Control Clinical Pharmacy and Patient Safety
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
Zunilda Djanun*, Rudyanto S**, Yulia Rosa***, *Dept. Clinical Pharmacology FMUI/CMH, **ICU CMH, *** Dept. Clinical Microbiology FMUI.
Antimicrobial Resistance patterns among nosocomial gram negative bacilli by E-test and disc diffusion methods in Sina and Imam Hospital.
Systematic review + meta-analysis: 69 (quasi-)randomised trials: N=7,863 pts with sepsis: any BL monoTx vs any combination of BL + AG: N (studies) : same.
General Principles of Antimicrobial Therapy. Concept #1: The guiding principle of antibiotic selection Antibiotic coverage should be kept to the narrowest.
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
Hospital Acquired Pneumonia(HAP): is defined as a pneumonia which occurs after 48 hours of admission to hospital. Hospital Acquired Pneumonia(HAP): is.
The Rational Use of Antibiotics
Prediction and Prevention of Emergence of Resistance of Clinically Used Antibacterials Fernando Baquero Dpt. Microbiology, Ramón y Cajal Hospìtal Madrid,
Acute Bacterial Otitis Media Summary and Charge to the Committee Renata Albrecht, M.D. Division of Special Pathogen and Immunologic Drug Products ODEIV,
MICROBIOLOGICAL EPIDEMIOLOGY OF RESPIRATORY SPECIMENS IN ICU PATIENTS Dr Farooq Cheema, Dr Waseem Tariq, Dr Raja Ishtiaq, Dr Tabassum Qureshi, Dr Vincent.
Országos Epidemiológiai Központ National Center for Epidemiology, Budapest, Hungary Activities in Hungary for preventing AMR and controlling HCAI Emese.
Diamantis P. Kofteridis, Christina Alexopoulou, Antonios Valachis, Sofia Maraki, Dimitra Dimopoulou Clinical Infectious Diseases 2010; 51(11):1238–1244.
Is a Strategy Based on Routine Endotracheal Cultures the Best Way to Prescribe Antibiotics in Ventilator-Associated Pneumonia? CHEST 2013; 144(1):63-71.
Tigecycline use in serious nosocomial infections: a drug use evaluation Matteo Bassetti*, Laura Nicolini, Ernestina Repetto, Elda Righi, Valerio Del Bono,
Multi-Resistant Gram Negative Microorganisms St Elisabeth Hospital Curacao.
Robert G. Sawyer- University of Virginia.  None.
IMPORTANT ANTIBIOTICS AND ANTIMICROBIAL RESISTANCE A Presentation By Ms R.Venkatajothi, MSc., MPhil, PhD Senior Lecturer Department of Microbiology Faculty.
HAP and VAP Guidelines Update
Antimicrobial Stewardship
Mycoplasma genitalium and macrolide resistance in pelvic inflammatory disease (PID) Gillian Dean1, Jennifer Whetham1, Suneeta Soni1, Rachel Pitt2, Sarah.
ANTI-MICROBIAL USAGE IN THE COMMUNITY AND RESISTANCE IN E.COLI
Dr.Mowna Karthick M.D MICROBIOLOGY
Use of antibiotics.
Antimicrobial treatments and their mechanisms of action
The Role of the Microbiology Laboratory in AMS programs
Average susceptibility
Background Goals Methods Conclusions Results
Antibiotics sensitivity of microorganism causing nosocomial infections
Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times  F.B. Spencker, L. Staber, T. Lietz,
Hospital Antibiotic Stewardship Programs
GLOBAL POINT PREVALENCE SURVEY OF ANTIMICROBIAL CONSUMPTION AND RESISTANCE (GLOBAL-PPS): RESULTS OF ANTIMICROBIAL PRESCRIBING IN INDIA Dr. Sanjeev K Singh.
Empirical antibiotic treatment algorithm for hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP). Empirical antibiotic treatment algorithm.
The need for new antibiotics
Antibiotic usage and the incidence of resistance
Evolving problems with resistant pathogens
Volume 151, Issue 4, Pages (April 2017)
Antimicrobial resistance
Presentation transcript:

What intervention on the use or dosing of antibiotics work to decrease resistance? Jan. 18, 2007 Sung-Ching Pan

Antibiotics control strategies Conan MacDougall and Ron E. Polk, CLINICAL MICROBIOLOGY REVIEWS, 2005 Mutation prevention dose Agriculture use Combination therapy

Antibiotics control Relationship between antibiotics usage and resistance –Ecological study Penicillin use and penicillin resistant S. pneumononas (PRSP) Antibiotics use (3rd cephalosporin, macrolide and fluroquilolone) and MRSA

Antibiotics control Relationship between antibiotics usage and resistance –Individual study AntibioticDepartmental consumption b Prior specific antibiotic c Prior treatment with any other antibiotic c Gentamicin1.03 (0.70–1.50)2.12 (1.29–3.48)1.81 (1.40–2.33) Amikacin1.80 (1.00–3.24)2.40 (1.31–4.40)1.31 (1.49–2.20) Cefuroxime1.12 (1.01–1.23)3.24 (1.97–5.34)2.77 (1.99–3.87) Ceftazidime1.45 (1.19–1.76)3.88 (1.89–7.97)1.55 (1.18–2.04) Ciprofloxacin d 1.06 (0.57–1.97)4.05 (2.00–8.21)1.27 (0.62–2.70) Leibovici et al. J Antimicrob Chem, 2001

Antibiotics control Relationship between antibiotics usage and resistance- Temporal sequence? –Intervention-change –Discontinue intervention-reverse

Antibiotics control Education campaign Restriction of usage Single switch/ antibiotics cycling Combination therapy Mutation prevention dose Control use in agriculture

Education campaign HELENA SEPPALA, et al. NEJM 1997 Intervention In the end1991 *Physicians were reached mainly through the Finnish Medical Journal and lectures at national and local meetings for general practitioners.

Limitations Ecological study, hard to control confounding After the intervention stop, what will happen? The problem of this strategy: Decrease use of macrolide, but increase use of other antibiotics, other resistance? –“the total rate of use of antimicrobial agents remained unchanged”

Education campaign (hospital/individual level) Some researches study the behavior change of antibiotics prescription after education campaign Education campaign- antibiotics resistance? Publication bias? Combination with other infection control strategies

Antibiotics control Education campaign Restriction of usage Single switch/ antibiotics cycling Combination therapy Mutation prevention dose Control use in agriculture

Restriction of usage White AC, CID, 1997 Prior authorization –Ben Taub General Hospital is a 575-bed urban teaching hospital in Houston. –Enforcement of the prior-authorization requirement began on 1 January –Intravenous amikacin, ceftazidime, ciprofloxacin, fluconazole, ofloxacin, and ticarcillin/clavulanate. –Faculty of the Infectious Diseases Service, Department of Medicine, were available 24 hours a day to provide antibiotic approval

Restriction of usage White AC, CID, 1997

Limitation: –Before –after study –Other intervention? in-service programs for surgical ICU staff on hand washing in November 1993 and July and August Need staffs support Restriction of usage White AC, CID, 1997

Antibiotics control Education campaign Restriction of usage Single switch/ antibiotics cycling Combination therapy Mutation prevention dose Control use in agriculture

Single switch Kollef MH, et al. AMm J Respir Crit Care Med, 1997 Switch of empirical for nosocomial pneumonia in ICU from ceftazidime to ciproxin Primary outcome: –incidence of ventilator-associated pneumonia (VAP) –nosocomial bacteremia Study design: –before(6 months) Vs. after (6 months)

Single switch Kollef MH, et al. AMm J Respir Crit Care Med, 1997

Before-after design Ceftazidime related drug resistance change did not clarified –Ceftazidime resistant P. aeruginosa –ESBL K. pneumonia or E.coli Problem with this strategy: –How about drug resistance to ciproxin?

Antibiotics control Education campaign Restriction of usage Single switch/ antibiotics cycling Combination therapy Mutation prevention dose Control use in agriculture

Routine cycling Raymond DP, et al. Crit Care Med 2001

Routine cycling

Agent A Agent B Time Resistance Limitation: 1.Short follow up time 2.Different patients population in the before-after setting CiproxinTazocincarbapenemcefepime

Routine cycling

Antibiotics control Education campaign Restriction of usage Single switch/ antibiotics cycling Combination therapy Mutation prevention dose Control use in agriculture

Combination therapy β-lactams+ aminoglycoside: –Pseudomonas Carbapemen+aminoglycoside –MDR Acinectobacter baumanii Work for therapeutic goal, but for resistance?

Combination therapy El Amari EB, et al. CID 2001 Case-control study Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates piperacillin, ceftazidime, imipenem, ciprofloxacin, or aminoglycosides

Combination therapy (meta-analysis of RCT) Bliziotis IA, CID 2005

Antibiotics control Education campaign Restriction of usage Single switch/ antibiotics cycling Combination therapy Mutation prevention dose Control use in agriculture

Concentration dependent Vs. Time dependent

The emergence of resistance

Mutation prevention concentration Describes the antibacterial concentration that inhibits the growth of the least- susceptible, single step mutant; The MIC of the least susceptible organism There is a low likelihood for spontaneous mutant formation at or above the MPC.

Mutation prevention concentration Limitation on clinical use –MPCs differ among the various fluoroquinolones against different pathogens –the MPC for each antibacterial agent is dependent on the genotypic profile of the organism. KD2138: parC KD2139: gyrA

Antibiotics control Education campaign Restriction of usage Single switch/ antibiotics cycling Combination therapy Pk/Pd, Mutation prevention dose Control use in agriculture

Agriculture use regulation Antibiotics resistance Animal pathogen Human pathogen

Study design Ramsay CE, J. Antimicrob. Chemother, 2003 Review of 306 studies of interventions to improve antimicrobial prescribing in hospitals, 70% did not meet the minimum criteria of the Cochrane Collaboration’s Effective Practice and Organization of Care Group. The most commonly excluded studies were those using uncontrolled before- and-after designs (46%) or inadequate interrupted time series analysis (24%).

Study design Interrupted time series with segmented regression: a method of analysis applied to before-and-after quasi-experimental study designs

Study design Mathematic modeling: –While a long-term follow up is needed for before-and-after quasi-experimental study designs –Control confounding